<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064319</url>
  </required_header>
  <id_info>
    <org_study_id>00112593</org_study_id>
    <secondary_id>R01DA054275</secondary_id>
    <nct_id>NCT05064319</nct_id>
  </id_info>
  <brief_title>Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders</brief_title>
  <official_title>Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study evaluates the effects of an FDA-approved medication Gabapentin in&#xD;
      individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be&#xD;
      assigned to take either Gabapentin or a matched placebo. Study medication will be taken for&#xD;
      17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed.&#xD;
      Questionnaires and clinical interview measures will be completed at study visits along with&#xD;
      consistent assessment of potential side effects from study medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in prefrontal GABA concentrations through Proton Magnetic Resonance Spectroscopy</measure>
    <time_frame>Baseline to end of treatment, approximately 17 days</time_frame>
    <description>Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Cannabis Use</condition>
  <condition>Schizoaffective Disorder, Bipolar Type</condition>
  <condition>Bipolar I Disorder</condition>
  <condition>Bipolar II Disorder</condition>
  <condition>Cannabis Use Disorder, Mild</condition>
  <condition>Cannabis Use Disorder, Moderate</condition>
  <condition>Cannabis Use Disorder, Severe</condition>
  <arm_group>
    <arm_group_label>Group A - Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.</description>
    <arm_group_label>Group A - Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.</description>
    <arm_group_label>Group B - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 18-65 years&#xD;
&#xD;
          2. Meet DSM-5 criteria for moderate or severe cannabis use disorder (CUD; within the past&#xD;
             3 months), provide a positive urine cannabinoid screen at baseline, and identify&#xD;
             cannabis as the primary substance of abuse&#xD;
&#xD;
          3. Meet DSM-5 criteria for bipolar I or II disorder (BD) or Schizoaffective Disorder,&#xD;
             Bipolar Type&#xD;
&#xD;
          4. Able to provide informed consent and read, understand, and accurately complete&#xD;
             assessment instruments&#xD;
&#xD;
          5. Willing to commit to medication treatment and follow-up assessments&#xD;
&#xD;
          6. Prescribed daily use of at least one mood stabilizing medication (i.e., lithium,&#xD;
             divalproex sodium, lamotrigine, carbamazepine, 2nd generation antipsychotic)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A primary psychiatric diagnosis other than BD (e.g., Schizophrenia)&#xD;
&#xD;
          2. Meet DSM-5 criteria for moderate or severe substance use disorder (other than cannabis&#xD;
             or tobacco) within the past 60 days&#xD;
&#xD;
          3. Any uncontrolled neurological condition (e.g., epilepsy) that could confound the&#xD;
             results of the study&#xD;
&#xD;
          4. Any history of brain injury with loss of consciousness greater than 5 minutes&#xD;
&#xD;
          5. Any history of mental retardation, dementia, or recent electroconvulsive therapy (in&#xD;
             the past 3 months)&#xD;
&#xD;
          6. Any uncontrolled medical condition that may adversely affect the conduct of the study&#xD;
             or jeopardize the safety of the participant&#xD;
&#xD;
          7. Hepatocellular disease as indicated by plasma levels of liver transaminases (aspartate&#xD;
             transaminase, alanine transaminase) greater than 3 times the normal range&#xD;
&#xD;
          8. Renal insufficiency as indicated by plasma levels of creatinine greater than 2 times&#xD;
             the normal range&#xD;
&#xD;
          9. Concomitant use of medications that could interfere with glutamatergic/GABAergic&#xD;
             transmission (e.g., benzodiazepines, ceftriaxone, riluzole, memantine, ketamine,&#xD;
             topiramate, vigabatrin), due to potential confounding effects&#xD;
&#xD;
         10. Concomitant use of opioid medications, benzodiazepines, barbiturates, chloral hydrate,&#xD;
             sodium oxybate, or any other medication deemed to be hazardous if taken with&#xD;
             gabapentin&#xD;
&#xD;
         11. Azelastine, orphenadrine, oxomemazine, paraldehyde, and thalidomide are generally&#xD;
             contraindicated in patients taking gabapentin; as such, individuals taking these&#xD;
             medications will be excluded&#xD;
&#xD;
         12. Women of childbearing potential who are pregnant, lactating, or refuse adequate forms&#xD;
             of contraception&#xD;
&#xD;
         13. Current suicidal or homicidal risk&#xD;
&#xD;
         14. Baseline scores greater than 35 on the Montgomery-Asberg Depression Rating Scale or&#xD;
             greater than 25 on the Young Mania Rating Scale&#xD;
&#xD;
         15. Has taken gabapentin in the last month or experienced adverse effects/allergic&#xD;
             reaction (e.g., angioedema) from it at any time&#xD;
&#xD;
         16. Significant claustrophobia and/or past negative experiences with MRI&#xD;
&#xD;
         17. Presence of non-MRI safe materials in the body (e.g., ferrous metal implants,&#xD;
             pacemaker)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J Prisciandaro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Hix</last_name>
    <phone>843-792-7500</phone>
    <email>hixs@musc.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>James J. Prisciandaro</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

